Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
NCT03674567Phase 2Completed
- Sponsor
- RAPT Therapeutics
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of tivumecirnon in cancer, sponsored by RAPT Therapeutics. Started Sep 2018; status: completed.
02
Drugs
tivumecirnon
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03674567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674567.